Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AARD
AARD logo

AARD News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AARD News

Aardvark Therapeutics Q1 Financial Results Overview

8h agoseekingalpha

Aardvark Therapeutics Halts HERO Trial Amid Safety Concerns

3h agoPRnewswire

Aardvark Therapeutics Shares Plummet After Trial Halt

Apr 22 2026PRnewswire

Aardvark Therapeutics Shares Plunge After Trial Halt

Apr 10 2026PRnewswire

Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56%

Apr 09 2026Globenewswire

Aardvark Therapeutics Under Investigation for Securities Fraud

Mar 24 2026Globenewswire

AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8

Mar 24 2026moomoo

Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025

Mar 24 2026NASDAQ.COM

AARD Events

05/07 09:20
Aardvark CEO Discusses Progress on ARD-101 Trial
"We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community," said Tien Lee, Founder and Chief Executive Officer of Aardvark. "We remain focused on establishing a clear path forward for the Phase 3 HERO trial evaluating ARD-101 in PWS, our lead program, and look forward to providing an update in the second quarter."
03/23 19:20
Trump Postpones Strikes on Iranian Energy, Market Sentiment Improves
Hopes for de-escalation in the Middle East conflict helped restore positive sentiment as President Trump's Truth Social post that strikes on Iranian energy infrastructure would be postponed after "productive" talks with Tehran boosted equities and dented geopolitical premium in the energy markets.  Consumer Discretionary and Materials were the best performing areas on the benchmark S&P 500, though all 11 sectors ended Monday in the positive - including Energy in spite of Oil prices falling back below $90 per barrel.  In the opening hour of the evening session, S&P 500 futures  are up another 0.2% and Nasdaq 100 is trading up 0.3% while WTI Crude is just off the closing lows above $89.  In precious metals, risk aversion which had boosted USD and punished Gold and Silver prices has reversed, and the two contracts are trading firmer around $4.435 and $70 per ounce respectively.Among the key headlines of the afterhours session continued to remind investors that the primary source of concern are still present.  Core Labsissued a below-consensus Q1 pre-announcement as the company cited regional instability in the Middle East, including client-driven project delays, travel constraints, and supply-chain disruptions. Private Credit worries also cropped up via reports from Bloomberg stating that Apollo Globalhas joined some of the other asset managers in capping private equity redemptions due to high volume of requests by investors to liquidate their positions.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -BARKup 6.4%Bionano Genomicsup 4.1%DOWN AFTER EARNINGS -Core Laboratoriesdown 1.8% after Q1 pre-announcementAardvark Therapeuticsdown 1.5%ALSO LOWER -Comtech Telecommunicationsdown 3.9% after equity offeringApollo Global Managementdown 2.1% after Bloomberg report of capped private equity redemptions
03/23 17:20
Aardvark Therapeutics Files $400M Mixed Securities Shelf
Aardvark Therapeutics files $400M mixed securities shelf

AARD Monitor News

No data

No data

AARD Earnings Analysis

No Data

No Data

People Also Watch